Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 23, 2018

View Archived Issues

Unprecedented benefit seen with maintenance olaparib following platinum response in ovarian cancer

Prdx6 as a new therapeutic target to restore muscle loss in type 2 diabetes-associated sarcopenia

First-in-human data presented for CTLA-4 inhibitor MK-1308

Mitotech initiates phase III study of SkQ1 ophthalmic solution in patients with dry eye

Mitsubishi Tanabe Pharma and Pharma Foods enter strategic research collaboration

Initial clinical data presented for BET inhibitor BMS-986158

Forbius initiates phase IIa study of AVID-100 for squamous NSCLC with EGFR overexpression

MC2 reports topline phase II data on MC2-03 for moderate to severe dry eye

Topline results from phase IIb study of dapirolizumab pegol in SLE

Achaogen to share data from LpxC inhibitor antibiotic research program on SPARK platform

Vascular BioSciences awarded phase II STTR grant to develop CAR peptide for the treatment of PAH

Novel role for MYH13 in aniridina

Disruption of actin-binding by PLS3 mutations causes congenital diaphragmatic hernia

mGlu4 PET radioligand [11C]PXT-012253 superior to [18F]PXT012251 in brains of nonhuman primates

First clinical data presented for the CD44v6 inhibitor AMC-303

New tracer for prostate cancer [18F]PSMA-7 enters clinical use

Genentech and Roche divulge MAP4K1 inhibitors

Reservoir SMACdown could fight latent HIV

Takeda Pharmaceutical presents PDE4 and PDE5 inhibitors

Transparent fish literally gives insights into vertebrate brain

Enzyme instead of antibody to kick smoking habit?

Methionine manipulation expands protein toolbox

XW Laboratories discloses new SCN2A and SCN9A blockers

Takeda Pharmaceutical and Scohia Pharma identify free fatty acid FFA1 receptor agonists

AstraZeneca patents Mcl-1 inhibitors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 21, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 21, 2026.
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...